Results from Genelux Corporation's Phase 1b Trial of GL-ONC1 in Recurrent Ovarian Cancer to be presented at the ASCO Annual Meeting 2018

Tags:   Phase 1   Ovarian Cancer   Oncology  

Promising safety data, immune activation and anti-tumor activity are documented in this trial.

SAN DIEGO, June 4, 2018 /PRNewswire/ -- Genelux Corporation, a privately-held biopharmaceutical company focused on the development of its proprietary oncolytic immunotherapy platform, today announced data from its Phase 1b trial evaluating its lead product candidate,  GL-ONC1, in recurrent ovarian cancer.  GL-ONC1 demonstrated a favorable safety profile and clinical benefits, which support further investigation in its ongoing Phase 2 VIRO-15 Study: Oncolytic Vaccinia Immunotherapy in Recurrent Ovarian Cancer. 

The results will be presented by lead investigator, Dr. Robert Holloway, from Florida Hospital Cancer Institute at the upcoming 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, being held June 1-5, 2018, in Chicago, IL.

---

---

"Heavily pretreated patients with late-stage platinum-resistant/refractory ovarian cancer face a poor prognosis, and would otherwise be considered for palliative care versus continuing drug therapies with diminishing clinical response," said Paul Scigalla, M.D., Ph.D., Chief Medical Officer of Genelux. "The positive results from this trial along with supporting data demonstrating mechanisms of action are therefore very encouraging. We look forward to the completion of VIRO-15."

Data from the Phase 1b trial are outlined below.

Abstract Number: 5577

Abstract Title: Phase 1b study of oncolytic vaccinia virus GL-ONC1 in recurrent ovarian cancer

Session Title/Date/Time: Gynecologic Cancer, 6/4/2018, Poster Session 1:15-4:45 PM

Abstract Highlights: The open-label, single-arm, monotherapy, dose-escalation study (https://clinicaltrials.gov/ct2/show/NCT02759588) treated eleven heavily pretreated patients (pts) with end-stage recurrent ovarian cancer (ROC).  Patient characteristics include: # of prior lines: 3-4 (n=3), ≥ 5 (n=8); ECOG 0 (n=7) or 1 (n=4); ascites/pleural effusion (n=9); and having progressive disease at baseline (n=10). There were two dose cohorts: 3 × 109 (Cohort 1: n=6) or 1 × 1010 (Cohort 2: n=5) plaque forming units of GL-ONC1 administered per day on 2 consecutive days.

A Phase 2 trial (VIRO-15) is currently enrolling, and future studies combining GL-ONC1 and other immune therapies and/or chemotherapy are under consideration.

---

---

About GL-ONC1 GL-ONC1 is an attenuated therapeutic vaccinia virus.  Clinical results in over 100 subjects treated in Genelux studies have shown GL-ONC1 is well tolerated with documented antitumor activities and clinical benefits.

About Genelux CorporationHeadquartered in San Diego, California, Genelux Corporation is a leader in oncolytic immunotherapy, utilizing its potent CHOICE™ discovery platform to develop a library of proprietary, oncolytic vaccinia virus-based diagnostic and therapeutic candidates in oncology. 

For more information please visit www.genelux.com. 

ContactInvestor Relations[email protected] (909) 307-9300

SOURCE Genelux Corporation

http://www.genelux.com

Cision Distribution 888-776-0942 from 8 AM - 9 PM ET